The estimated Net Worth of Christopher C. Lemasters is at least $3.52 Milion dollars as of 14 February 2019. Christopher Lemasters owns over 60,000 units of Mirati Therapeutics Inc stock worth over $3,522,000 and over the last 8 years Christopher sold MRTX stock worth over $0.
Christopher has made over 1 trades of the Mirati Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Christopher exercised 60,000 units of MRTX stock worth $387,000 on 14 February 2019.
The largest trade Christopher's ever made was exercising 60,000 units of Mirati Therapeutics Inc stock on 14 February 2019 worth over $387,000. On average, Christopher trades about 12,000 units every 0 days since 2016. As of 14 February 2019 Christopher still owns at least 60,000 units of Mirati Therapeutics Inc stock.
You can see the complete history of Christopher Lemasters stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O MIRATI THERAPEUTICS, INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... a Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: